{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.2","upperLimit":"71.3","value":"66.27"},{"groupId":"OG001","lowerLimit":"69.2","upperLimit":"77.1","value":"73.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"448"}],"units":"Participants"}],"description":"Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, will be estimated for each randomized arm. (Closed effective February 15, 2017)","dispersionType":"95% Confidence Interval","groups":[{"description":"Non-DS VHR patients receive a modified MBFM-IMHDM regimen that contains a second IM (Control Arm)","id":"OG000","title":"Non-DS VHR B-ALL Control Arm"},{"description":"Non-DS VHR patients receive cyclophosphamide + etoposide containing regimen (Experimental Arm 1)","id":"OG001","title":"Non-DS VHR B-ALL Exp Arm1"}],"paramType":"NUMBER","populationDescription":"(includes patients from AALL0932). Inevaluable and ineligible patients were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"Up to 10 years","title":"Toxicity and Tolerability of Experimental Arm 1 and Control Arm in Patients With VHR B-ALL","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}